Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Addex Therapeutics ( (CH:ADXN) ) is now available.
Addex Therapeutics has entered into a collaboration agreement with Sinntaxis AB to explore the use of mGlu5 inhibitors for brain injury recovery. This partnership will involve evaluating Addex’s dipraglurant, a promising candidate for treating functional recovery in patients with brain injuries, potentially enhancing Addex’s position in addressing unmet medical needs in neurological recovery.
More about Addex Therapeutics
Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders. The company’s lead drug candidate, dipraglurant, is under evaluation for brain injury recovery, including post-stroke and traumatic brain injury. Addex also has interests in substance use disorders and chronic cough treatments, and holds a stake in Neurosterix LLC, which is advancing programs for schizophrenia and mood disorders.
Average Trading Volume: 100
Current Market Cap: $34.8M
See more data about ADXN stock on TipRanks’ Stock Analysis page.